Bianchini, G.; Arpino, G.; Biganzoli, L.; Lonardi, S.; Puglisi, F.; Santini, D.; Lambertini, M.; Pappagallo, G.
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers 2022, 14, 1022.
https://doi.org/10.3390/cancers14041022
AMA Style
Bianchini G, Arpino G, Biganzoli L, Lonardi S, Puglisi F, Santini D, Lambertini M, Pappagallo G.
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers. 2022; 14(4):1022.
https://doi.org/10.3390/cancers14041022
Chicago/Turabian Style
Bianchini, Giampaolo, Grazia Arpino, Laura Biganzoli, Sara Lonardi, Fabio Puglisi, Daniele Santini, Matteo Lambertini, and Giovanni Pappagallo.
2022. "Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel" Cancers 14, no. 4: 1022.
https://doi.org/10.3390/cancers14041022
APA Style
Bianchini, G., Arpino, G., Biganzoli, L., Lonardi, S., Puglisi, F., Santini, D., Lambertini, M., & Pappagallo, G.
(2022). Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers, 14(4), 1022.
https://doi.org/10.3390/cancers14041022
